Loading
Every dated change on the records linked to Basal cell carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Two different questions get muddled here and they have different answers. Will this one come back: usually not, and the risk depends on what it was and how it was treated. In the Dutch randomised trial of high-risk facial basal cell carcinoma, ten-year recurrence was 4.4 percent after Mohs and 12.2 percent after standard excision for primary tumours, and 3.9 against 13.5 percent for recurrent ones; the same trial found that 56 percent of the recurrences of primary tumours appeared more than five years after treatment, which is why a clear five years is reassuring but is not the end of the story for a high-risk lesion on the face. Will I get another one: probably, and sooner than you would guess. In a meta-analysis of 17 studies, the three-year cumulative risk of a further basal cell carcinoma after a first was 44 percent, at least ten times the rate of first tumours in a comparable population, while the risk of a squamous cell carcinoma after a basal cell carcinoma was 6 percent. Those are cohort figures rather than a prediction for you, and they are about new cancers on damaged skin rather than this one returning. What follow-up is offered follows from that, and it is lighter than most people expect. The BAD says not everyone needs it, that people are usually discharged if the recurrence risk is low and they are not at high risk of future skin cancers, and that it is considered for advanced disease, a high risk of recurrence, or a high risk of multiple cancers such as people with weakened immune systems or genetic syndromes. Cancer Research UK says an early basal cell carcinoma may mean a single follow-up appointment and then none. Being discharged is not being dropped: it is a transfer of the surveillance to you, and both the BAD and Cancer Research UK are explicit about what you are then meant to do. The BAD puts a frequency on it, once a month, with someone else looking at the places you cannot see; Cancer Research UK asks you to know what your skin normally looks like and does not name an interval. Both say to go to the GP for any mark that is growing, changing, bleeding or not healing, including a change where this one was treated.
Post hoc analyses in 17 participants suggested that patidegib topical gel reduced the number of new surgically eligible basal cell carcinomas and the level of hedgehog signalling, with minimal adverse effects; no pre-specified endpoint was met.
Freedom from treatment failure at five years 77.
For a large facial basal cell carcinoma where the operation would cost an eyelid or a nostril, a hedgehog inhibitor can be given first. VISMONEO gave vismodegib for a mean of 6.0 months to 55 patients with a mean lesion size of 47.3 mm and downstaged the planned surgery in 44 of them (80 per cent, 67 to 90), with 27 complete responses of which 25 were proved on biopsy. The part usually left out belongs in the conversation: at three years 16 of those 44 patients had a known recurrence, 36 per cent. The drug changes the operation, it does not replace it.
Objective response by independent central review in 26 of 84 patients (31 per cent, 95 per cent confidence interval 21 to 42) with five complete responses; grade 3 or 4 treatment-emergent adverse events in 48 per cent.
Surgical downstaging in 44 of 55 patients (80 per cent, 95 per cent confidence interval 67 to 90) with 27 complete responses, an objective response rate of 71 per cent, and recurrence in 16 of the 44 downstaged patients (36 per cent) by three years.
A milestone in how this cancer is treated.
Objective response in 26 of 84 patients (31 per cent) whose disease had progressed on or who could not tolerate a hedgehog inhibitor.
Clinical success at three years 84 per cent with imiquimod against 98 per cent with surgery (relative risk 0.
Investigator-assessed response 68.
TA489 recommendation 1.1 does not recommend vismodegib for metastatic or locally advanced basal cell carcinoma, on uncertain evidence and a cost per quality-adjusted life year far above 30,000 pounds.
1,215 patients in 36 countries: response 68.5 per cent in locally advanced disease, adverse events in 98 per cent and a median treatment duration of 8.6 months.
Locally advanced BCC recurrent after surgery or radiation, or not candidates
Objective response at 200 mg: 43% in locally advanced and 15% in metastatic basal cell carcinoma (central review).
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Metastatic BCC or locally advanced BCC recurrent after surgery or not amenable to surgery/radiation
Objective response 43% in locally advanced and 30% in metastatic basal cell carcinoma (independent review).
First hedgehog-pathway inhibitor.
The creams and the light are licensed for the thin superficial form, and stretching them to the thicker nodular form has been tested twice with the same answer. Methyl aminolevulinate photodynamic therapy against excision gave five-year recurrence of 14 against 4 per cent and a sustained complete response of 76 against 96 per cent, with an excellent or good cosmetic outcome in 87 against 54 per cent. Scraping the tumour off first and then applying imiquimod, tested in the SCIN trial, gave freedom from treatment failure at five years of 77.8 against 98.2 per cent, a relative risk of failure of 15.93. Both are defensible for someone who cannot or will not have facial surgery, and neither is equivalent to it.
Five-year recurrence 14 per cent after methyl aminolevulinate photodynamic therapy against 4 per cent after excision (sustained complete response 76 against 96 per cent, p=0.